Next Article in Journal
The Role of Arrestin Domain-Containing 3 in Regulating Endocytic Recycling and Extracellular Vesicle Sorting of Integrin β4 in Breast Cancer
Next Article in Special Issue
BRCA1-Dependent Transcriptional Regulation: Implication in Tissue-Specific Tumor Suppression
Previous Article in Journal
Intracellular Iron Chelation by a Novel Compound, C7, Reactivates Epstein–Barr Virus (EBV) Lytic Cycle via the ERK-Autophagy Axis in EBV-Positive Epithelial Cancers
Previous Article in Special Issue
Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer
Open AccessFeature PaperReview

Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?

1
Department of Medical Oncology, Institut Paoli-Calmettes, 13009 Marseille, France
2
CRCM-Predictive Oncology laboratory, Institut Paoli-Calmettes, Inserm U1068, CNRS UMR7258, Aix-Marseille Univ, 13009 Marseille, France
*
Author to whom correspondence should be addressed.
Cancers 2018, 10(12), 506; https://doi.org/10.3390/cancers10120506
Received: 8 November 2018 / Revised: 27 November 2018 / Accepted: 9 December 2018 / Published: 11 December 2018
(This article belongs to the Special Issue BRCA Mutations and Cancer)
Breast cancers (BC) associated with germline mutations of BRCA1/2 represent 3–5% of cases. BRCA1/2-associated BC have biological features leading to genomic instability and potential sensitivity to DNA damaging agents, including poly(ADP-ribose) polymerase (PARP) and platinum agents. In this review, we will summarize clinical trials of chemotherapy and PARP inhibitors (PARPi), alone or in combination, at the early or late stage of BRCA1/2-associated BC. We will also present the mechanisms of resistance to PARPi as well as the new therapeutic strategies of association with PARPi. Finally, we will discuss under which conditions the use of DNA damaging agents can be extended to the BRCA1/2-wild type population, the BRCAness concept. View Full-Text
Keywords: BRCA; DNA-damaging agents; platinum; poly(ADP)-ribose polymerase BRCA; DNA-damaging agents; platinum; poly(ADP)-ribose polymerase
Show Figures

Figure 1

MDPI and ACS Style

Nicolas, E.; Bertucci, F.; Sabatier, R.; Gonçalves, A. Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives? Cancers 2018, 10, 506.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop